江苏又有一家公司上市，首日涨幅超270%，市值超160亿元！

Core Viewpoint - Jiangyin Jiyuan Group Co., Ltd. successfully listed on the A-share market, marking a significant milestone for the company and the Jiangsu IPO landscape [3][8]. Company Overview - Jiyuan Group, founded in September 2002 by Zhou Jingshi, specializes in the research and production of dietary nutritional supplements [5]. - The company is led by General Manager Long Ling, who has played a key role in the commercialization of 22 patented products [5]. Product Portfolio - The main products include HMB raw materials, glucosamine series, chondroitin sulfate, and formulations, with projected revenues for 2024 being CNY 293 million, CNY 180 million, CNY 90 million, and CNY 350 million respectively [5]. - HMB raw materials hold a global market share of 53.34%, ranking first, largely due to the significant contribution from Abbott, which accounts for 73.35% of HMB revenue [5][6]. Market Position - The glucosamine series has a global market share of 12.61%, with clients including Blackmores and Royal Canin [6]. - Chondroitin sulfate targets the high-end pet nutrition market, with a global market share of 0.96% [6]. Financial Performance - Revenue figures from 2021 to 2024 are projected at CNY 801 million, CNY 947 million, CNY 892 million, and CNY 1 billion, with net profits of CNY 110 million, CNY 142 million, CNY 160 million, and CNY 174 million respectively [6]. IPO Details - The IPO application was accepted in March 2023, and the company successfully went public in July 2023, raising CNY 544 million with a net amount of CNY 480 million after expenses [8][9]. - The company issued 50.01 million shares at an initial price of CNY 10.88 per share, with a first-day closing price of CNY 40.75, reflecting a 274.54% increase and a market capitalization of CNY 16.3 billion [9]. Fund Utilization - The funds raised will be allocated to various projects, including CNY 206 million for a nutritional health raw material production base, CNY 147 million for expanding a production line, CNY 99.14 million for a technology innovation center, and CNY 150 million for working capital [8].